Bicara Therapeutics (BCAX) vs Latigo Biotherapeutics (LTGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bicara Therapeutics is the larger company by market cap ($1.12 billion vs $980.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | LTGO |
|---|---|---|
| Share price | $16.88 | $14.79 |
| Market cap | $1.12B | $980.24M |
| 1-day change | +2.80% | -4.73% |
| YTD return | -2.44% | — |
| 1-year return | -9.63% | — |
| EPS (TTM) | $-3.08 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.99 | $25.93 |
| 52-week low | $13.70 | $14.60 |
| Distance from 52-week high | -45.53% | -42.98% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +110.31% | +253.40% |
| Average volume | 610.46K | 394.20K |
| Shares outstanding | 66.17M | 66.30M |
| Employees | 103 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
BCAX vs LTGO FAQ
Which is bigger, Bicara Therapeutics or Latigo Biotherapeutics?
Bicara Therapeutics (BCAX) is larger, with a market capitalization of $1.12B compared with $980.24M for Latigo Biotherapeutics (LTGO).
Are Bicara Therapeutics and Latigo Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.